Dynamics, Regulation and Function of p53 in Single Cells

单细胞中 p53 的动态、调控和功能

• 批准号: 10534806
• 负责人: Galit Lahav
• 金额: $ 11.74万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-01-01 至 2025-12-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10534806
• 关键词: 3-Dimensional; Address; Affect; Architecture; Cell Death; Cells; Cellular Stress; Clinical; Conflict (Psychology); DNA Damage; Data; Development; Dose; Environment; Gene Combinations; Gene Expression; Genes; Goals; Human; Image; Immune; Immune system; Immunotherapy; Individual; Knowledge; Link; Malignant Neoplasms; Mediating; Normal Cell; Outcome; Pathway interactions; Pattern; Play; Population; Post-Translational Protein Processing; Process; Proteins; RNA; Radiation; Regulation; Role; Schedule; Signal Transduction; Stimulus; System; TP53 gene; Therapeutic; Time; Translating; Tumor Suppressor Proteins; Work; cancer cell; cancer therapy; cell killing; clinically relevant; combinatorial; imaging system; in vivo; inhibitor; insight; mutant; neoplastic cell; new technology; novel; overexpression; programs; response; single-cell RNA sequencing; targeted treatment; transcription factor; tumor

The dynamics of signaling systems are critical for controlling gene expression programs and cellular outcomes. The tumor suppressor protein p53 is a transcription factor orchestrating the response to cellular stresses, and we previously found that its dynamics (changes in its protein levels over time) following DNA damage depend on the stimulus and play a role in determining whether a cell will survive or die. However, many questions remain about how different cellular contexts influence p53 dynamics and ultimate cellular outcomes, how p53 chooses between conflicting cellular outcomes, and how p53 dynamics can best be leveraged for therapeutic purposes. The goals of our work are to obtain a comprehensive quantitative understanding of how p53 dynamics regulate cellular outcomes in single cells and to apply our findings to address clinical needs. The cellular environment can influence p53 dynamics, therefore we will first investigate how p53 dynamics are regulated by factors such as 3D cellular architecture in cultured tumor spheroids and in in vivo tumors. We will then investigate the dynamics and cellular outcomes of cancer-associated p53 mutants in cultured and in vivo settings. The effects of p53 dynamical patterns on gene expression will be determined in single cells by using novel technology that supports integrating live imaging data of p53 dynamics with single-cell RNA sequencing. We will also investigate how p53 dynamics influence gene expression at the RNA and protein levels, as well as the dynamics of p53 post-translational modifications in bulk populations. These studies will reveal the impact that p53 dynamical patterns have on the RNA and protein of its target genes, and how the combinations of these dynamical patterns guide cellular outcomes. We will also use our live-imaging systems to determine how clinically-relevant therapeutic approaches can be optimized to induce the desired p53 dynamics and cellular outcomes in cancer. We will determine how the doses and timings of radiation fractions affect p53 dynamics and function, and optimize the schedule of fractions for inducing tumor cell death via p53-mediated mechanisms. Many cancers overexpress the p53 inhibitors Mdm2 or Mdmx and are susceptible to their inhibition. Through quantifying and modulating p53 dynamics we will determine how to fine-tune their inhibition to sensitize Mdm2 or Mdmx overexpressing cells to DNA damage while sparing healthy cells. Tumor cells can be cleared by the immune system, and this process is influenced by the tumors' gene expression programs. Therefore, we will investigate how p53 dynamics influence interactions between tumor cells and immune cells, and work towards optimizing combinations of p53-targeting therapeutics with immunotherapies to maximize tumor cell killing by the immune system. In total, these studies will provide new mechanistic insights into the links between p53 dynamics and function in controlling cell fates, and will inform novel combinatorial therapeutic approaches to cancer treatments.

信号系统的动力学对于控制基因表达程序和细胞结果至关重要。 肿瘤抑制蛋白p53是一种转录因子，协调对细胞应激的反应， 我们以前发现，DNA损伤后其动力学（蛋白质水平随时间的变化）取决于 并在决定细胞存活或死亡方面发挥作用。然而，许多问题仍然存在 关于不同的细胞环境如何影响p53动力学和最终的细胞结果， 之间的冲突细胞的结果，以及如何p53动力学可以最好地利用治疗目的。 我们的工作目标是获得一个全面的定量了解如何p53动态调节 我们希望能够在单细胞中获得细胞结果，并将我们的发现应用于临床需求。细胞环境 可以影响p53的动态，因此，我们将首先研究如何p53动态调节的因素， 作为培养的肿瘤球体和体内肿瘤中的3D细胞结构。然后我们将调查 在培养和体内环境中癌症相关p53突变体的动力学和细胞结果。的影响 p53对基因表达的动力学模式将在单细胞中通过使用新的技术来确定， 支持整合p53动态的实时成像数据与单细胞RNA测序。我们亦会研究 p53动力学如何影响RNA和蛋白质水平的基因表达，以及p53的动力学 大量群体中的翻译后修饰。这些研究将揭示p53动力学的影响， 模式对靶基因的RNA和蛋白质的影响，以及这些动力学模式的组合如何影响靶基因的RNA和蛋白质。 引导细胞结果。我们还将使用我们的实时成像系统来确定临床相关性 可以优化治疗方法以在癌症中诱导期望的p53动力学和细胞结果。 我们将确定辐射剂量和时间如何影响p53的动力学和功能， 优化用于通过p53介导的机制诱导肿瘤细胞死亡的级分的时间表。许多癌症 过表达p53抑制剂Mdm2或Mdmx，并且对它们的抑制敏感。通过量化和 调节p53动力学，我们将确定如何微调其抑制以敏化Mdm 2或MDMX 过度表达细胞以破坏DNA，同时保留健康细胞。肿瘤细胞可以被免疫系统清除 这一过程受到肿瘤基因表达程序的影响。因此，我们将调查 p53动力学如何影响肿瘤细胞和免疫细胞之间的相互作用， 靶向p53的治疗剂与免疫治疗剂的组合， 系统总之，这些研究将为p53动力学和细胞凋亡之间的联系提供新的机制见解。 在控制细胞命运中起作用，并将为癌症治疗提供新的组合治疗方法。